"A Phase III Double-blind Randomised Study Assessing the Efficacy andSafety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-lineTreatment for Patients with Histologically Confirmed, Locally Advanced(Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC)"

drug protocol number

D3614C00001

drug sponsor

AstraZeneca

drug study

Capivasertib

drug trial site

King Fahad Specialist Hospital (Dammam), King Abdullah Medical City (Makkah), Specialized Medical Center (Riyadh)

drug status

Ongoing

drug phase